Login / Signup

Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS).

D ThaçiA PinterM SebastianC TermeerMichael SticherlingS GerdesS WegnerS KrampeH BartzC RauschA MenschK Eyerich
Published in: The British journal of dermatology (2020)
Guselkumab demonstrated superiority over FAE in systemic-treatment-naive patients with moderate-to-severe plaque psoriasis through 24 weeks.
Keyphrases
  • coronary artery disease
  • hiv infected
  • clinical trial
  • high intensity
  • randomized controlled trial
  • drug induced
  • replacement therapy
  • phase iii
  • double blind
  • hidradenitis suppurativa